ArticleCanadian respiratory journal2026
WuYeLuGen Granule Attenuates Bleomycin-Induced Pulmonary Fibrosis in Rats by Inhibiting the TGF-β1/Smad Signaling Pathway and Epithelial-Mesenchymal Transition.
Article in Canadian respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary fibrosis is a chronic disease characterized by progressive interstitial lung changes affecting alveolar epithelial cells and pulmonary vessels. Following COVID-19, it has emerged as a significant sequela in severe cases, often with a poor prognosis. WuYeLuGen (WYLG) Granule, derived by Xue's Wuye Lugen Granule, exerts effects of replenishing qi, nourishing yin, clearing heat, and resolving dampness. While clinical and experimental studies provide evidence to support WYLG's efficacy against early-stage pulmonary fibrosis, its underlying mechanisms remain incompletely understood. Methods: Active components of WYLG were identified using LC-MS/MS. CCK8 assays were performed to determine the optimal concentrations of WYLG-containing serum and TGF-β1. WYLG granules were administered to bleomycin (BLM)-induced rats and WYLG-containing serum was applied to TGF-β1-stimulated rat pulmonary fibroblasts (RPFs). Hematoxylin-Eosin (HE) and Masson staining were used to assess the protective effects of WYLG on rat lung tissues, while enzyme-linked immunosorbent assay (ELISA) was employed to evaluate lung inflammation. Flow cytometry analyzed RPF cell proliferation, scratch assays examined cell migration, and Western blot detected the expression of fibrotic and pathway-related proteins. Immunofluorescence was used to confirm the efficacy of WYLG in reducing RPF cell fibrosis. Results: LC-MS/MS identified 18 active components in WYLG, primarily derived from Conclusions: WYLG markedly alleviates pulmonary fibrosis both in vivo and in vitro by inhibiting the TGF-β1/Smad signaling pathway and regulating epithelial-to-mesenchymal transition, highlighting its potential as a therapeutic agent for progressive pulmonary fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.